[Treatment of chronic coronary insufficiency].
D000328:Adult; D000368:Aged; D045930:Anabolic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000787:Angina Pectoris / Q000188:drug therapy / Q000517:prevention & control; D001783:Blood Flow Velocity; D001794:Blood Pressure / Q000187:drug effects; D001810:Blood Volume / Q000187:drug effects; D002214:Capsules; D002908:Chronic Disease; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008722:Methods; D008875:Middle Aged; D009963:Orotic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D010208:Papaverine / Q000627:therapeutic use; D010919:Placebos; D011299:Prenylamine / Q000627:therapeutic use; D011433:Propranolol / Q000008:administration & dosage / Q000627:therapeutic use*; D013607:Tablets; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D045930:Anabolic Agents; D002214:Capsules; D010919:Placebos; D013607:Tablets; D014665:Vasodilator Agents; D009963:Orotic Acid; D011433:Propranolol; D010208:Papaverine; D011299:Prenylamine
Lechenie khronicheskoĭ koronarnoĭ nedostatochnosti.